# A Study to Evaluate the Antiviral Activity and Safety of HH-003 Injection in Subjects With HBeAg-Negative Chronic Hepatitis B Treated With Nucleos(t)Ide Reverse Transcriptase Inhibitors

> **NCT05839639** · PHASE2 · COMPLETED · sponsor: **Huahui Health** · enrollment: 73 (actual)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** NrtIs
- **DRUG:** HH-003
- **DRUG:** HH-003+NrtIs

## Key facts

- **NCT ID:** NCT05839639
- **Lead sponsor:** Huahui Health
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-09
- **Primary completion:** 2022-12-05
- **Final completion:** 2023-05-17
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2023-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05839639

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05839639, "A Study to Evaluate the Antiviral Activity and Safety of HH-003 Injection in Subjects With HBeAg-Negative Chronic Hepatitis B Treated With Nucleos(t)Ide Reverse Transcriptase Inhibitors". Retrieved via AI Analytics 2026-09-26 from https://api.ai-analytics.org/clinical/NCT05839639. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*